(-)-Caryophyllene Oxide

(-)-Caryophyllene Oxide

SCHEMBL24110084

C=C1CC[C@@H]2O[C@]2(C)CC[C@@H]2[C@@H]1CC2(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 10/20 1.00
FTH1 P02794 1/20 1.00
CYP2C9 P11712 1/20 1.00
CYP2C19 P33261 1/20 1.00
CNR2 P34972 2/20 0.51
PPARA Q07869 2/20 0.51
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 1/20 0.47
PTPN1 P18031 1/20 0.41
HSP90AA1 P07900 1/20 0.40
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(-)-Caryophyllene Oxide SCHEMBL16489852 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL18788522 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL1532444 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL127077 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL24110118 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL17857878 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL676309 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL16769854 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL21349931 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2
(-)-Caryophyllene Oxide SCHEMBL26189380 1.00 CYP3A4 (1.00) CYP3A4FTH1CYP2C9CYP2C19CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025231514-A1 ANTIVIRAL FORMULATIONS Vapour Science (AU) 2025-11-13 WO claimed
US-20240238177-A1 USE OF VOLATILE COMPOUNDS TO MODULATE THE PERCEPTION OF FLORAL MUGUET FIRMENICH SA (CH) 2024-07-18 US claimed
US-20230380428-A1 BIODEGRADABLE CLEANING PRODUCTS, METHODS OF PRODUCTION, AND THEIR COMPOSITIONS SUSTAINABLE COMMUNITY DEV LLC (US) 2023-11-30 US claimed
US-20220323371-A1 TERPENE-ENRICHED CANNABINOID COMPOSITION BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) 2022-10-13 US claimed
EP-3993780-A1 HEMP EXTRACT FOR TREATMENT OF PAIN, CANCER AND EPILEPSY IN ANIMALS Ellevet Sciences (US) 2022-05-11 EP claimed
WO-2022081174-A1 BIODEGRADABLE CLEANING PRODUCTS, METHODS OF PRODUCTION, AND THEIR COMPOSITIONS SUSTAINABLE COMMUNITY DEVELOPMENT, LLC (US) 2022-04-21 WO claimed
WO-2025231514-A1 ANTIVIRAL FORMULATIONS Vapour Science (AU) 2025-11-13 WO disclosed
US-12435053-B2 Process for preparing caryophyllene oxide SYMRISE AG (DE) 2025-10-07 US disclosed
EP-4552652-A2 TERPENE-ENRICHED CANNABINOID COMPOSITION Buzzelet Development And Technologies Ltd (IL) 2025-05-14 EP disclosed
US-20240316136-A1 ANESTHETIC METHOD OF SPOTTED SEABASS WITH PLANT ESSENTIAL OILS SHANGHAI OCEAN UNIVERSITY (CN) 2024-09-26 US disclosed
EP-4426119-A1 COMPOSITION FOR USE IN PLANTS AND USES THEREOF Biotech Tricopharming Research S.L. (ES) 2024-09-11 EP disclosed
US-20240238177-A1 USE OF VOLATILE COMPOUNDS TO MODULATE THE PERCEPTION OF FLORAL MUGUET FIRMENICH SA (CH) 2024-07-18 US disclosed
US-11985973-B2 Insect repelling composition GLOBAL BIOLIFE INC. (US) 2024-05-21 US disclosed
US-11618869-B2 Aromatized effervescent wine and method of making same Rozoy, Clément (FR) 2023-04-04 US disclosed
US-20220323371-A1 TERPENE-ENRICHED CANNABINOID COMPOSITION BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) 2022-10-13 US disclosed
US-20220159950-A1 INSECT REPELLING COMPOSITION GLOBAL BIOLIFE INC. 2022-05-26 US disclosed
EP-3993780-A1 HEMP EXTRACT FOR TREATMENT OF PAIN, CANCER AND EPILEPSY IN ANIMALS Ellevet Sciences (US) 2022-05-11 EP disclosed
WO-2022081174-A1 BIODEGRADABLE CLEANING PRODUCTS, METHODS OF PRODUCTION, AND THEIR COMPOSITIONS SUSTAINABLE COMMUNITY DEVELOPMENT, LLC (US) 2022-04-21 WO disclosed
US-11246310-B2 Insect repelling composition GLOBAL BIOLIFE INC. (US) 2022-02-15 US disclosed
US-20210387959-A1 PROCESS FOR PREPARING CARYOPHYLLENE OXIDE SYMRISE AG (DE) 2021-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435053-B2 Process for preparing caryophyllene oxide POR, SQLE, CBR3 CYP3A4 99/4885FTH1 845/4885CYP2C9 132/4885
US-20210387959-A1 PROCESS FOR PREPARING CARYOPHYLLENE OXIDE POR, SQLE, CBR3 CYP3A4 99/4885FTH1 845/4885CYP2C9 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.